Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

Table 1 Whole genome bisulfite sequencing of 13 human samples

Sample ID	Status	Tissue	Origin	Total reads	Coverage genome	Coverage CpG	Average methylation	SE^a	SE covered^b
CD19	Normal	B cells	Primary	318714023	6.0	14.1	76.0	688	99.0 %
Brain	Normal	Brain (white matter)	Primary	557237398	11.1	7.0	77.1	1067	99.6 %
Breast	Normal	Breast	Primary	606872747	15.1	32.1	73.0	1099	99.5 %
Colon	Normal	Colon	Primary	609043678	13.7	24.3	69.6	1023	99.4 %
Lung	Normal	Lung	Primary	333333332	7.2	8.7	74.4	1286	99.1 %
Colon_P	Cancer	Colorectal cancer	Primary	670281443	16.7	24.6	66.5	1023	99.4 %
Colon_M	Cancer	Colorectal cancer metastasis	Primary	652566967	16.3	24.7	62.4	1023	99.4 %
MDA-MB-468PT	Cancer	Breast cancer	Cell line	626288553	15.4	37.6	57.1	1099	99.4 %
MDA-MB-468LN	Cancer	Breast cancer metastasis	Cell line	600134926	14.3	37.1	42.8	1099	99.5 %
U87MG	Cancer	Glioblastoma	Cell line	281524883	6.3	8.5	55.7	1067	99.6 %
H1437	Cancer	Lung adenocarcinoma	Cell line	333333332	7.9	10.3	48.1	1286	99.1 %
H1672	Cancer	Small cell lung cancer	Cell line	329691560	7.4	10.5	65.6	1286	99.1 %
H157	Cancer	Lung squamous cell cancer	Cell line	333333332	7.8	10.7	41.8	1286	99.2 %

^a SE is the number of super-enhancer regions determined in the respective normal tissue samples [11]
^bSE covered is the percentage of super-enhancers covered by WGBS (>50 % of CpG sites)

ISSN: 1474-760X